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Previously, surgical repair for neonates with pulmonary atresia and intact ventricular
septum (PAIVS) involved: either 1) a palliative systemic-to-pulmonary shunt, or 2) a
corrective pulmonary valvulotomy together with reconstruction of the right ventricular
outflow tract.
1 However, the mortality and the morbidity remained high after surgery,
especially in those with severe hypoplastic right ventricles with or without infundibulum,
non-confluent pulmonary arteries, ventriculocoronary communication (VCC), and right
ventricle-dependent coronary circulation (RVDCC).
2 Recently, transcatheter
radiofrequency pulmonary valvulotomy and valvuloplasty (RPVV) emerged as a
promising alternative to surgical pulmonary valvulotomy for PAIVS in patients with
favorable morphology of the right ventricle, the tricuspid valve, and the pulmonary valve.
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Purpose : Outcomes in 6 neonates with pulmonary atresia and intact ventricular septum (PAIVS) undergoing
radiofrequency pulmonary valvulotomy and valvuloplasty (RPVV) were reported to identify the factors favorable for RPVV
as the treatment of choice. Materials and Methods: From May 2000 to January 2008, 6 patients with PAIVS were included
in this retrospective study. They were aged 1 day to 90 days old. Study modalities included review of recordings of
presentations and profiles of chest radiography, electrocardiography, echocardiography, and cardiac catheterization with
angiography. Hemodynamic profiles from the echocardiography and the cardiac catheterization were analyzed. Results:
Echocardiography showed severe tricuspid regurgitation, membranous atresia of the pulmonary valve, intact ventricular
septum, patent ductus arteriosus, and hypoplastic right ventricle in 6 patients. The pulmonary valve annulus were 4.2 to 6.9
mm in diameters, and those of the tricuspid valve were 7.1 to 10.1 mm. Elevated serum level of cardiac enzymes were found
in 1 patient with ventriculocoronary communication (VCC). At cardiac catheterization, the ratio of systolic pressure of the right
ventricle to that of the left ventricle ranged from 1.43 to 2.33 before RPVV, and from 0.54 to 1.15 after RPVV (p=0.027). The
pressure gradients ranged from 76 to 136 mmHg before RPVV, and from 15 to 39 mmHg after RPVV (p=0.028). The
echocardiographic gradients ranged from 16 to 32 mmHg within 24 hours after RPVV, and from 15 to 50 mmHg at the
follow-ups. Conclusion: RPVV can be a treatment of choice for neonates with PAIVS, if there is patent infundibulum, no
right-ventricular dependent coronary circulation, and adequate tricuspid valve and pulmonary valve.
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pediatric cardiologists performing RPVV, provided that there
was presence of patent infundibulum and absence of RVDCC.
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From May 2000 to January 2008, 6 consecutive patients (4
male and 2 female) with PAIVS were included in this retro-
spective study. They were aged from 1 day to 90 days old.
Patients having pulmonary atresia associated with ventricular
septal defect, Ebstein’s anomaly, or other congenital heart
diseases were excluded from the study. Study modalities
included review of profiles of recordings of the clinical features,
arterial blood gas, chest radiographs, electrocardiograms, two-
dimensional echocardiography with Doppler (Acuson 128XP/10c,
Mountain View, CA, USA), and cardiac catheterization with
angiography. In all 6 patients, diagnostic angiography (right
ventriculogram, left ventriculogram, and ascending aortogram)
was performed to visualize the morphology of the right
ventricle and VCC and define the course and distribution of the
coronary arteries as they arose from the aorta. RPVV was
performed after obtaining informed consent from their parents.
Using a standard Seldinger maneuver, cardiac catheterization
was performed through the femoral vein and artery in each
patient, to whom intravenous prostaglandin E1 (PGE1), intravenous
antibiotics, mechanic ventilation, and local anesthesia were
applied beforehand. Prior to performing RPVV, systolic
pressures of the right ventricle (sRV) and main pulmonary
artery (sPA) were measured simultaneously by 2 catheters. The
sRV was measured by a 4-French (or 5-French) Multi-Purpose
Catheter (Cordis, Miami, FL, USA), a Right Coronary Judkins
Catheter (Cordis, Miami, FL, USA), or a Berman Catheter
(Arrow, Mt. Holly, NJ, USA) approaching the right ventricle
antegradely from the femoral vein, and the sPA was measured
by a 4-French Multi-Purpose Catheter approaching the main
pulmonary artery retrogradely from the femoral artery via the
patent ductus arteriosus (PDA). The pressure gradient was
determined by the equation of sRV-sPA, i.e., subtracting
systolic pressure of the main pulmonary artery from that of the
right ventricle. A flexible 2-French unipolar radiofrequency
catheter (CERABLATE PA 120, Grenzach-Wyhlen,
Germany), which was passed through a 5-French Right
Coronary Judkins Catheter or a 6-French Coronary Guiding
Catheter (TRANSIT, Cordis, Miami Lakes, USA) was used to
deliver radiofrequency energy of 2 to 15 watts (W) for 3 to 5
seconds from the generator (HAT 200 S, Grenzach-Wyhlen,
Germany) to perforate the atretic pulmonary valve. Initially, a
small coronary balloon catheter (2.0 mm in diameter and 20.0
mm in length; HAYATE, Terumo, Tokyo, Japan) was used to
dilate the already open pulmonary valve, and subsequently,
some larger coronary balloon catheters (3.0 mm and 4.0 mm in
diameter; HAYATE, Terumo, Tokyo, Japan; 5.0 mm and 6.0
mm in diameter Maverick, Boston, MN, USA) and even
Wanda balloon catheter (8.0 mm in diameter; Business Park,
Allybrit, Galway, Ireland) were applied to dilate gradationally.
After RPVV, the pressure gradients across the pulmonary valve
were obtained, according to the records of the pressure tracings,
by pulling back the balloon catheter from the main pulmonary
artery to the right ventricle. Hemodynamic data, obtained
within 24 hours, of the echocardiography and cardiac catheteri-
zation were analyzed to evaluate the initial results of RPVV.
Transvalvular pressure gradients by echocardiography and
oxygen saturations by peripheral pulse oximeter were recorded
for each patient at follow-ups to evaluate the final outcomes of
RPVV.
The clinical profiles and hemodynamics of 6 neonates with
PAIVS treated by RPVV are summarized in Table 1 and Table
2, respectively. Echocardiography with Doppler showed dilated
right atrium, severe tricuspid regurgitation, small atrial septal
defect secundum with restrictive right-to-left shunt, hypoplastic
right ventricle with visible right ventricular outflow tract,
membranous atresia of pulmonary valve with visible pulmo-
nary annulus and main pulmonary trunk, confluent pulmonary
arteries without branch pulmonary artery stenosis, intact
ventricular septum, and PDA in 6 all cases. Patient 2 had non-
obstructive VCC, but none of these 6 patients had RVDCC,
judged by diagnostic angiography. Before RPVV, a 4-French
Multi-Purpose Catheter can be situated in the main pulmonary
trunk serving as the “landmark catheter” in 2 cases with
upstream PDA. However, the process of putting a “landmark
catheter” into the main pulmonary artery was demanding in 4
patients with downstream PDA. The sRV/sLV ratios ranged
from 1.43 to 2.33 (1.90 ± 0.30, median 1.88) before RPVV,
and from 0.54 to 1.15 (0.80 ± 0.27, median 0.76) after RPVV
(p = 0.027). The pressure gradients of sRV-sPA ranged from 76
to 136 mmHg (104.2 ± 24.8, median 99.5 mmHg) before
RPVV, and from 15 to 39 mmHg (27.5 ± 9.8, median 27.5
mmHg) after RPVV (p = 0.028). The echocardiographic
pressure gradients ranged from 16 to 32 mmHg (25.2 ± 5.7,
median 25.5 mmHg) within 24 hours after RPVV.
Five patients, except Patient 1, could be weaned off mecha-
nical ventilation and intravenous PGE1 without surgery. Three
of these 5 patients (Patients 3, 5, and 6) were discharged
smoothly after RPVV without significant medical events during
their hospitalizations. Two of these 5 patients (Patients 2 and 4)
suffered from 2 episodes of nosocomial infection in each; with
bacterial pneumonia and Rotaviral gastroenteritis in Patient 2
and bacterial pneumonia and septicemia in Patient 4. These
episodes of infection were under control by intravenous third-
generation cephalosporins and other supportive care. Patient 2
had elevated serum levels of creatine kinase (CK; 2030 U/L >
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Table 1. Clinical Profiles of 6 Patients with PAIVS Treated by RPVV Using a Flexible 2-French Radiofrequency Catheter Followed by 
Gradational Balloon Dilatation
No / Age / Gender 1/14 d/M 2/90 d/M 3/1 d/M 4/1 d/F 5/2 d/M 6/1 d/F
SpO2  (at onset) 70% 80 65 68 60 80
Liver span (cm) 3.5 4.0 3.5 3.5 3.0 3.0
CTR (%) 73 71 72 72 68 64
ASD II (mm) 2.5 3.2 2.8 3.0 2.4 2.7
VCC Negative Positive Negative Negative Negative Negative
PGE1 (ng/kg/min) 20, 40, 60 20, 40, 60 20, 40 20, 40, 60 20 20
PDA morphology Downstream Downstream Downstream Upstream Downstream Upstream
TGRM Nil Nil Nil Positive Nil Positive
RF energy, time 5 W, 4 sec 5 W, 5 sec 4 W, 5 sec  5 W, 3 sec 2 W, 3 sec 15 W, 5 sec
Medical events 1) cyanosis  1) MI (with elevated  Nil 1) pneumonia Nil Nil
(SpO2 50%) and  CK/CK-MB/Tn-I) 2) sepsis
PHT due to RPVC  2) pneumonia 3) cyanosis (SpO2 68%)
s/p effective RPVV  3) Rotaviral infection and PHT due to
(SpO2 90%) and BTS 4) regression of MI  RPVC s/p effective
2) treated with NOi  and VCC s/p RPVV; RPVV (SpO2 > 92%)
(SpO2 88%) 5) propanolol 4) treated with NOi 
3) digitalis, furoxemide, (SpO2 above 95%)
captopril, and aspirin 5) propanolol
Surgical events BTS (right, stenotic;  Nil Nil Nil Nil Nil
left, patent)
Sequelae Nil Nil Nil Nil Nil Nil
SpO2 (at FU) 82 - 88% 82 - 85% 96 -100% 92 - 93% 94 - 96% 97 - 99%
ASD II, atrial septal defect secundum; BTS, Blalock-Taussig shunt; CK, creatine kinase; CK-MB, myocardial fraction of thecreatine kinase;  
CTR, cardiothoracic ratios calculated on the plain chest films; FU, follow-ups; MI, myocardial ischemia; NOi, nitric oxide inhalation; PAIVS, pulmonary atresia and
intact ventricular septum; PDA, patent ductus arteriosus; PGE1, prostaglandin E1; PHT, pulmonary hypertension; RF, radiofrequency; RPVC, reactive pulmonary
vasoconstriction; RPVV, radiofrequency pulmonary valvulotomy and valvuloplasty; sec, seconds; SpO2, saturation of oxygen; s/p, status post; TGRM, transductal
guidewire railing maneuver; Tn-I, Troponin-I; VCC, ventriculocoronary communication that is not right-ventricular dependent; W, watt.
Table 2. Hemodynamics of 6 Patients with PAIVS Treated by RPVV Using a Flexible 2-French Radiofrequency Catheter Followed by 
Gradational Balloon Dilatation
No / PV/TV vs Z-values Balloon modality  Catheter PG before and after RPVV Echo PG (mmHg)
Age / PV Z TV Z Length (20 mm) sRV-sPA (mmHg) sRV/sLV (%) within F-U at the
Sex mm mm Diameter in mm Before  After Before After 24 hrs age of
1/14 d/M  6.0  - 3.7 7.1 - 1.7 2.0; 6.0 76 31 1.73 0.81 25 18; (91 m)
2/90 d/M 5.1 - 4.5 7.5 - 1.5 2.0; 5.0; 6.0 136 15 1.97 0.54 16 15; (55 m)
3/1 d/M 6.6 - 3.1 10.0 - 0.9 2.0; 4.0; 6.0; 8.0 105 39 2.13 0.70 32 16; (34 m)
4/1 d/F 4.2 - 5.5 8.8 - 0.1 2.0; 3.0; 6.0 131 37 2.33 1.15 26 21; (25 m)
5/2 d/M 6.9 - 2.6 9.1 - 0.8 2.0; 4.0; 6.0; 8.0 83 24 1.78 1.09 22 35; (15 m)
6/1 d/F 6.3 - 2.2 10.1 - 0.2 2.0; 4.0; 6.0; 8.0 94 19 1.48 0.53 30 50; (5 m)
Range [76, 136] [15, 39] [1.43, 2.33] [0.54, 1.15] [16, 32] [15, 50]
Median 99.5 27.5 1.88 0.76 25.5 19.5
Mean ± SD 104.2±24.8 27.5±9.8 1.90± 0.30 0.80± 0.27 25.2±5.7 25.8±13.9
pvalue* 0.028 0.027 0.917
d, day; Echo, echocardiographic; F, female; M, male; m, month; PG, pressure gradient; PV, pulmonary valve; RPVV, radiofrequency pulmonary valvulotomy and 
valvuloplasty; sRV-sPA, systolic pressure in mmHg of the right ventricle minus that of the main pulmonary artery; sRV/sLV, ratio expressed in percentage (%) of the
systolic pressure of the right ventricle to that of the left ventricle; SD, standard deviation; TV, tricuspid valve; Vmax, the maximal velocity in meters per second.
*pvalue by Wilcoxon signed rank test.upper normal limit of 224 U/L), myocardial fraction of CK
(CK-MB; 429 U/L > upper normal limit of 6.3 U/L), and
Troponin-I (Tn-I; 48.20 ng/mL > upper normal limit of 0.04
ng/mL), which were suggestive of myocardial ischemia due to
VCC before RPVV. All parameters regressed to normal levels
after RPVV. Patients 1 and 4 suffered from blue spells after
RPVV. In both patients, echocardiography with Doppler and
bubble-contrast test showed spontaneous closure of the PDA,
severe tricuspid regurgitation, unchanged pressure gradient
across the pulmonary valve, and significant interatrial right-to-
left shunt via the atrial septal defect secundum, which may be
due to either inadequate effective pulmonary blood flow from
the right ventricle with post-procedure infundibular spasm or
pulmonary hypertension with reactive pulmonary vasoconst-
riction. Patient 1 did not initially respond to inhalation of nitric
oxide and construction of a right Blalock-Taussig shunt. He
could be weaned off mechanical ventilation, intravenous PGE1,
and inhalation of nitric oxide after reconstruction of a patent left
Blalock-Taussig shunt and application of beta-blocker
(propanolol). He was discharged with an oxygen saturation of
88%, and treated with oral digitalis, furoxemide, captopril, and
aspirin at the outpatient clinic. We did not use a larger 8-mm
balloon in Patient 1, because infundibular spasm cannot be
ruled out. Septicemia was documented in Patient 4 and was the
suspected precipitating factor of blue spell or pulmonary
hypertension. After administrations of intravenous third-
generation cephalosporins and inhalation of nitric oxide,
oxygen saturations could maintain above 95%. The PDA and
the ASD II remained open in 1 patient (Patient 2) after RPVV
and discontinuance of intravenous PGE1.
The echocardiographic pressure gradients ranged from 15 to
50 mmHg at the follow-ups of 5 to 91 months. Fascinatingly,
the VCC disappeared in the follow-up echocardiography and
right ventriculography in Patient 2. Four of 6 patients had
oxygen saturations above 92%, and 2 patients had saturations
above 82%. None of them had neurological sequelae on the
follow-up evaluations.
RPVV has recently emerged as a promising alternative to
surgical valvulotomy in patients with PAIVS, in whom 4 key
points merit our attentions, including 1) echocardiographic
diagnosis, 2) angiographic diagnosis and characteristics, 3)
interventional techniques, and 4) mechanism of cyanosis and
adjunctive treatment of pulmonary hypertension following
RPVV.
First of all, echocardiography with color Doppler is
considered useful to identify the ductus, to determine the
intracardiac pathology, and to guide us in making a decision to
prescribe intravenous PGE1 to keep the ductus patent as an
emergency medical therapy. Absence of patent infundibulum
and presence of VCC could be confirmed and alarmed
beforehand. Besides, the morphologic heterogeneity of the right
ventricle and the coronary arteries can be assessed, and the
diameters of the tricuspid valve and the pulmonary valve can be
measured and computed to Z values.
3 So far, transcatheter
pulmonary valvotomy was considered a definitive treatment in
the neonates with PAIVS, if the Z-value of the tricuspid valve ≥
-0.1 and that of the pulmonary valve ≥ -4.1.
5 In the present
study, the Z-values of the pulmonary valves ranged from -2.2 to
-5.5, and those of the tricuspid valves ranged from -0.1 to -1.7.
Blalock-Taussig shunt was needed only in one patient (Patient
1), whose Z-value of the pulmonary valve was -3.7 and that of
the tricuspid valve -1.7. However, 2 of 6 patients (Patients 2
and 4) had smaller pulmonary valve Z-values (-4.5 and -5.5)
and tricuspid valve Z-values (-1.5 and -0.1), and they went
through successful RPVV without any surgical intervention.
The Z-values of the pulmonary valve and the tricuspid valve
were not the sine qua non determinants for successful RPVV in
patients with PAIVS. Smaller Z-values of the pulmonary valve
and the tricuspid valve are not absolute contraindications for
considering RPVV alone as a definitive treatment in patients
with PAIVS.
Secondly, the course and distribution of the coronary arteries
should be carefully delineated, and the morphology of the right
ventricle, the PDA, and the right atrial appendage be clearly
defined or visualized in the diagnostic angiography before
performing RPVV. Decisions concerning the surgical or trans-
catheter right ventricular decompression (RVD) in patients with
PAIVS have been evolved in four decades and focused initially
on the size and the number of partites constituing the right
ventricle (inflow, trabecular, and outflow),
1,2 on the cut-off Z-
values of the tricuspid valves and the pulmonary valves,
3 and
finally on the presence of VCC with RVDCC.
4 RVDCC was
defined as the presence of VCC associated with obstruction of
more than 1 (>1) major coronary artery so that the major
portion of the left ventricular blood supply was derived from
the right ventricle.
6-10 A significant portion of PAIVS patients
was found to have VCC (30% to 60%),
3,6,10-12 and RVDCC (9%
to 26%).
3,4 Theoretically, RVD could result in a right ventricular
steal phenomenon causing diastolic runoff (of the coronary
blood flow) from the aorta to the right ventricle, lessening
myocardial perfusion, jeopadizing the myocardium to infarc-
tion,
10 and potentially unmasking RVDCC.
6 RVDCC is the
factor that precludes RVD in PAIVS patients by surgery
10 or by
RPVV.
4 Potential right ventricular steal caused by VCC alone,
but without RVDCC, did not preclude successful RVD.
10 In this
report, Patient 2 had PAIVS associated with VCC, but without
RVDCC, successfully underwent RVD by RPVV without
incurring significant sequalae. Thus, precise definition of
coronary arterial anatomy by angiography is warranted in
neonates with PAIVS.
4,8,10 Another decisive factor predicting the
feasibility of establishing continuity between the right ventricle
and the pulmonary artery is the distance between the distal right
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DISCUSSIONventricular outflow tract and the proximal main pulmonary
artery. There are 2 ways to ascertain this distance. Usually, we
used a targeting catheter to label its tip on the membranous
pulmonary valve from the right ventricular outflow tract,
confirmed its preferred lie by contrast injection or blood
drawing manually, and applied a landmark catheter in the
ductus or near the ductus in the descending aorta for cine
contrast injection. Another way to show this distance was
described as double catheter technique.
13 Based on clinical
implication, PDA in patients with PAIVS could be angiogra-
phically classified into two kinds of morphology: 1) upstream
PDA from the descending aorta, and 2) downstream PDA from
the transverse aortic arch. The clinical implication of ductal
morphology cannot be overemphasized, because transaortic
approach of PDA downstream from the transverse aortic arch
to place a landmark catheter into the pulmonary artery will be
demanding. With the aid of a guiding wire, a 4-French Multi-
Purpose Catheter could be guided to advance with less difficulty
from the downstream PDA to the main pulmonary artery,
serving as a landmark catheter.
14,15 The transaortic approach
from the descending aorta will be much easier in cases with
upstream PDA. Good placement of a landmark catheter,
referenced as a “roadmap”, would be instructive during
transcatheter perforation.
16 Finally, the anatomic lie of the right
atrial appendage could be mistaken as that of the right
ventricular outflow tract in patients with PAIVS, in whom the
right atrium and the right atrial appendage are hugely dilated
due to severe tricuspid regurgitation. As we can imagine, a fatal
catastrophe will ensue if the right atrial appendage is the
mistaken targeted site of radiofrequency perforation.
Thirdly, RPVV was conventionally performed by approac-
hing antegradely from the femoral vein, with only rare excep-
tions that were unconventionally performed by approaching
retrogradely or transductally from the descending aorta,
17 or
from the right carotid artery.
18 Rather, the unconventional or
transductal approach presented some problems intrinsic to
neonates with PAIVS: 1) vascular compromise after cannula-
tion of the artery using a larger catheter, 2) vessel damage or
vasoconstriction caused by sawing action of the catheter on the
ductus, which is the sole source of pulmonary blood flow, and 3)
a more difficult angle to perforate the membrane centrically
from a larger main pulmonary trunk above into a smaller right
ventricular outflow tract below, which is liable to cause cardiac
tamponade or perforation.
16 Application of flexible 2-French
radiofrequency catheters offered some advantages to the
pediatric cardiologist performing RPVV for the neonates with
PAIVS, including: 1) avoidance of vascular compromise by
using smaller catheters for cannulation, 2) timesaving without
exchanging guidewire for balloon dilatation, and 3) avoidance
of cardiac perforation frequently encountered by using a
standard, but stiffer, 5-French radiofrequency catheter that will
straighten the 5-French guiding catheter and result in cephalad
misdirection toward the free wall of the right ventricular
outflow tract.
16,18
After successful radiofrequency valvulotomy, gradational
balloon valvuloplasty is recommended. Initially, a small
coronary balloon catheter (2.0 mm in diameter and 20.0 mm in
length, HAYATE, Terumo, Tokyo, Japan) could be used to
predilate the already perforated pulmonary valve. Later on,
some larger coronary balloon catheters could be used to dilate
the pulmonary valves gradationally.
Another adjunctive role of the ductus for balloon valvulo-
plasty is exemplified via the creation of a transductal guidewire
rail,
19 which involved using a snare catheter to grasp the guide-
wire from the descending aorta that may facilitate the balloon
catheter to pass across the small pulmonary valve opening.
However, the prerequisite is that the ductus should be upstream,
rather than downstream, in morphology. Prolonged stay or
irritation of a guidewire within the downstream ductus during
manipulation to create a transductal guidewire rail may cause
ductal constriction and can be lethal. If a transductal guidewire
rail is created, one should be careful not to pull the guidewire
forcefully with the snare catheter to avoid a sawing action on
the ductus, which is harmful.
19 Thus, transductal railing maneu-
ver should carefully be used in patients with upstream PDA.
However, a transductal railing maneuver can be appallingly
demanding in patients with downstream PDA.
Finally, the mechanism of cyanosis or persistent oxygen
desaturation should be sought out desperately before appli-
cation of surgery or inhalation of the nitric oxide. Anatomic
obstruction due to decreased pulmonary venous inflow (obstruc-
tive total anomalous pulmonary venous connection, congenital
mitral stenosis, and congenital pulmonary vein stenosis) or
inadequate pulmonary arterial blood flow (stenotic or obstruc-
tive Blalock-Taussig shunt or infundibular spasm) should be
discriminated from the reactive pulmonary vasoconstriction.
19
In this report, Patients 1 and 4 suffered greatly after RPVV. In
both patients, echocardiography with Doppler and bubble-
contrast test showed spontaneous closure of the PDA, severe
tricuspid regurgitation, unchanged pressure gradient across the
pulmonary valve, and significant interatrial right-to-left shunt
via the atrial septal defect secundum, which may be due to
either inadequate effective pulmonary blood flow from the right
ventricle with post-procedure infundibular spasm or pulmonary
hypertension with reactive pulmonary vasoconstriction. A
clinical trial of inhaled nitric oxide may help differentiate
anatomic obstruction from reactive pulmonary vasocons-
triction.
20,21 Failure to respond to inhaled nitric oxide in neonates
after cardiac surgery should prompt investigations for further
surgical correction. However, unexpected cyanosis can be
caused by reactive pulmonary vasoconstriction in newborns
after placement of a patent systemic-to-pulmonary shunt.
19 In
Patient 1, the first episode of cyanosis was unresponsive to
inhaled nitric oxide, which might have been related to inade-
quate pulmonary blood flow due to either a stenotic Blalock-
Taussig shunt or infundibular spasm. In spite of placing a
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second patent Blalock-Taussig shunt, a second episode of
cyanosis due to pulmonary hypertension occurred and respon-
ded well to nitric oxide inhalation. There are many possible
reasons for cyanosis after the interventional procedure in
patients with PAIVS, including infundibular spasm, spontaneous
closure of PDA, severe tricuspid regurgitation with restrictive
interatrial right-to-left shunt, and severe pulmonary regurgita-
tion due to pulmonary hypertension with reactive pulmonary
vasoconstriction. However, persistent pulmonary hypertension
with reactive pulmonary vasoconstriction after the procedure
may be a rare cause of cyanosis in PAIVS following RPVV.
Inhaled nitric oxide has been proved to be a potent selective
pulmonary vasodilator, which is effective in the management of
postoperative pulmonary hypertension in patients with conge-
nital heart disease.
22-26 However, in spite of routine application
in the clinical practice, nitric oxide inhalation has rarely been
documented in the English literature in the postoperative care of
patients with PAIVS treated by RPVV.
RPVV can be a treatment of choice for neonates with
PAIVS, provided that there is patent infundibulum and no
RVDCC. The cut-off values of the tricuspid valve and pulmo-
nary valve prerequisite for RPVV remain to be determined,
because of limitations of short-and mid-term follow-ups in a
small series of only 6 patients in the present study. Long-term
follow-up of their biventricular status is warranted to determine
the cut-off Z-values while considering RPVV as a definitive
treatment for patients with PAIVS. Though with potential right
ventricular steal in VCC, VCC alone did not preclude
performance of RPVV. Inhalation of nitric oxide can be used to
treat pulmonary hypertension and to increase oxygenation,
which would be helpful to wean patients off PGE1 and
mechnical ventilation before a second try of balloon dilatation
or surgical repair for patients with PAIVS.
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